Page last updated: 2024-11-06

floxuridine and Pancreatic Neoplasms

floxuridine has been researched along with Pancreatic Neoplasms in 37 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Research Excerpts

ExcerptRelevanceReference
"Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma."7.67Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986)
"Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)."5.31Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000)
"Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases."3.73Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. ( Amidon, GL; Landowski, CP; Song, X; Vig, BS, 2005)
"Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma."3.67Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986)
" In our previous studies with human gastrointestinal and breast cancers xenografted into nude mice, combination therapy with mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) [I] or cisplatin (CDDP), vindesine (VDS) and 5'-DFUR [II] produced higher response rates than single-agent therapy with any one of these drugs."3.67[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987)
"Gemcitabine 1,000 mg/m(2) was infused over 100 min (days 1, 8 and 15)."2.73Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. ( Bang, SJ; Joo, KR; Kim, H; Kim, MJ; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Shin, SJ, 2008)
"Gemcitabine accumulation was significantly enhanced in fibroblast-rich tumours compared with liver metastases and normal liver."1.48Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. ( Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C, 2018)
"Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance."1.37Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. ( Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU, 2011)
" The pharmacokinetic analysis of gemcitabine and dFdU was performed with high-performance liquid chromatography-tandem mass spectrometry assay in cycles 1 and 2."1.35Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. ( Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M, 2009)
"Experimentally, we studied a diploid colorectal cancer line heterozygous at TS to mimic three common TS genotypes of cancers."1.33Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. ( Brody, JR; Gallmeier, E; Hucl, T; Kern, SE; Murphy, KM; Winter, JM, 2006)
"Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)."1.31Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000)
"Animals with pancreatic cancer displayed focal uptake of both tracers."1.31In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. ( Glatting, G; Greten, FR; Neumaier, B; Reske, SN; Schmid, RM; Seitz, U; Vogg, AT; Wagner, M, 2001)
"Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum."1.30Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. ( Arber, N; Beger, HG; Danenberg, KD; Danenberg, PV; Korc, M; Kornmann, M, 1999)
"Doxifluridine (5-DFUR) is an orally active fluoropyrimidine, and its cytotoxic metabolite (5-FU) may concentrate in areas of high tumor vascularization."1.30Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. ( Artale, S; Bajetta, E; Bozzetti, F; Buzzoni, R; Di Bartolomeo, M; Mazzaferro, V; Ricci, SB; Stani, SC; Toffolatti, L, 1999)
"Three patients with primary hepatocellular carcinoma demonstrated less than 50% reduction in tumor size."1.27Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. ( Jones, LS; McCune, CS; Schwartz, SI, 1985)
"Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts."1.25Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975)

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-199015 (40.54)18.7374
1990's4 (10.81)18.2507
2000's11 (29.73)29.6817
2010's7 (18.92)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nambaru, PK1
Hübner, T1
Köck, K1
Mews, S1
Grube, M1
Payen, L1
Guitton, J1
Sendler, M1
Jedlitschky, G1
Rimmbach, C1
Rosskopf, D1
Kowalczyk, DW1
Kroemer, HK1
Weiss, FU1
Mayerle, J1
Lerch, MM1
Ritter, CA1
Han, H1
Wang, J1
Chen, T1
Yin, L1
Jin, Q1
Ji, J1
Hessmann, E1
Patzak, MS1
Klein, L1
Chen, N1
Kari, V1
Ramu, I1
Bapiro, TE1
Frese, KK1
Gopinathan, A1
Richards, FM1
Jodrell, DI1
Verbeke, C1
Li, X1
Heuchel, R1
Löhr, JM1
Johnsen, SA1
Gress, TM1
Ellenrieder, V1
Neesse, A1
Felici, A1
Di Segni, S1
Milella, M1
Colantonio, S1
Sperduti, I1
Nuvoli, B1
Contestabile, M1
Sacconi, A1
Zaratti, M1
Citro, G1
Cognetti, F1
Ohmine, K1
Kawaguchi, K1
Ohtsuki, S1
Motoi, F1
Egawa, S1
Unno, M1
Terasaki, T1
Tsume, Y1
Amidon, GL2
Ji, S1
Xu, J1
Zhang, B1
Xu, Y1
Liu, C1
Long, J1
Ni, Q1
Yu, X1
Patel, K1
Yerram, SR1
Azad, NA1
Kern, SE2
Takizawa, M1
Hirano, M1
Murakami, N1
Uno, Y1
Kikuchi, T1
Nozawa, H1
Hara, T1
Asaumi, Y1
Kikkawa, H1
Shibamoto, Y1
Mimasu, Y1
Tachi, Y1
Hatta, H1
Nishimoto, S1
SULLIVAN, RD3
NORCROSS, JW1
WATKINS, E1
CLIFTON, KH1
SZYBALSKI, W1
HEIDELBERGER, C1
GOLLIN, FF1
ANSFIELD, FJ2
VERMUND, H1
ZUREK, WZ1
Ardalan, B1
Lima, M1
Chung, HW1
Bang, SM1
Park, SW1
Chung, JB1
Kang, JK1
Kim, JW1
Seong, JS1
Lee, WJ1
Song, SY1
Landowski, CP1
Vig, BS1
Song, X1
Brody, JR1
Hucl, T1
Gallmeier, E1
Winter, JM1
Murphy, KM1
Kim, H1
Park, JH1
Shin, SJ1
Kim, MJ1
Bang, SJ1
Park, NH1
Nah, YW1
Nam, CW1
Joo, KR1
Min, YJ1
Sommadossi, JP2
Aubert, C1
Cano, JP2
Gouveia, J1
Ribaud, P1
Mathé, G1
Armstrong, RD1
Gesmonde, J1
Wu, T1
Cadman, E1
Chu, MY1
Naguib, FN1
Iltzsch, MH1
el Kouni, MH1
Chu, SH1
Cha, S1
Calabresi, P1
Matsuoka, H1
Seo, Y1
Ohshiro, T1
Adachi, E1
Nagamine, S1
Miyazaki, N1
Shiromizu, A1
Baba, H1
Kounoe, S1
Saito, T1
Robertson, JM1
Shewach, DS1
Lawrence, TS1
Kornmann, M1
Danenberg, KD1
Arber, N1
Beger, HG1
Danenberg, PV1
Korc, M1
Bajetta, E1
Di Bartolomeo, M1
Stani, SC1
Artale, S1
Ricci, SB1
Bozzetti, F1
Mazzaferro, V1
Toffolatti, L1
Buzzoni, R1
Delauter, BJ1
Ramanathan, RK1
Egorin, MJ1
Stover, LL1
Zuhowski, EG1
Plunkett, W1
Zamboni, WC1
Seitz, U1
Wagner, M1
Vogg, AT1
Glatting, G1
Neumaier, B1
Greten, FR1
Schmid, RM1
Reske, SN1
Tsuruta, K1
Okamoto, A1
Egawa, N1
Kamisawa, T1
Karasawa, K1
Takahashi, T1
Moertel, CG2
Schwartz, SI1
Jones, LS1
McCune, CS1
Malet-Martino, MC1
Faure, F1
Vialaneix, JP1
Palevody, C1
Hollande, E1
Martino, R1
Fujita, F1
Fujita, M1
Yamauchi, T1
Sakamoto, Y1
Shimozuma, K1
Inaba, H1
Taguchi, T1
Davis, HL1
Ramirez, G1
Miller, E1
Van Dyk, JJ1
Clarkson, BD1
Duschinsky, R1
Keller, O1
La Sala, E1
Krakoff, IH1

Reviews

3 reviews available for floxuridine and Pancreatic Neoplasms

ArticleYear
Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review.
    Pancreas, 2012, Volume: 41, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Female;

2012
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma.
    Cancer, 1996, Aug-01, Volume: 78, Issue:3 Suppl

    Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Combined Modality Therapy; Deoxycytidine; Floxur

1996
Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer.
    Journal of surgical oncology, 2001, Volume: 78, Issue:3

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administra

2001

Trials

4 trials available for floxuridine and Pancreatic Neoplasms

ArticleYear
A phase II trial of FUdR in patients with advanced pancreatic cancer.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:10

    Topics: Antimetabolites, Antineoplastic; Floxuridine; Humans; Pancreatic Neoplasms; Treatment Outcome

2004
A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2004, Dec-01, Volume: 60, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Gem

2004
Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
    Chemotherapy, 2008, Volume: 54, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D

2008
[Pharmacological study of 5'-DFUR oral administration and the clinical responses against gastrointestinal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch

1995

Other Studies

30 other studies available for floxuridine and Pancreatic Neoplasms

ArticleYear
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug R

2011
Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
    Journal of colloid and interface science, 2017, Dec-01, Volume: 507

    Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carri

2017
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
    Gut, 2018, Volume: 67, Issue:3

    Topics: 5'-Nucleotidase; Actins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cel

2018
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
    Clinical pharmacokinetics, 2009, Volume: 48, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neopla

2009
Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Pharmaceutical research, 2012, Volume: 29, Issue:7

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resista

2012
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.
    Molecules (Basel, Switzerland), 2012, Mar-26, Volume: 17, Issue:4

    Topics: Amino Acids; Antimetabolites, Antineoplastic; Cathepsin B; Cathepsin D; Cell Line, Tumor; Cell Proli

2012
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
    Oncotarget, 2012, Volume: 3, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Colorectal Neoplasms; Dose-Response Relations

2012
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr

2002
Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colony-Forming Units Assay; Female; Floxuri

2002
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
    The New England journal of medicine, 1964, Feb-13, Volume: 270

    Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo

1964
INCORPORATION OF I-125-LABELED IODODEOXYURIDINE INTO THE DEOXYRIBONUCLEIC ACID OF MURINE AND HUMAN TISSUES FOLLOWING THERAPEUTIC DOSES.
    Cancer research, 1963, Volume: 23

    Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Floxuridine; Geriatrics; Idoxuridine; Intestine, Small;

1963
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
    Cancer chemotherapy reports, 1964, Volume: 37

    Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf

1964
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:4

    Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line; Cell Line, Tumor; Ce

2005
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
    Cancer research, 2006, Oct-01, Volume: 66, Issue:19

    Topics: 5' Untranslated Regions; Alleles; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop

2006
Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans.
    Cancer research, 1983, Volume: 43, Issue:2

    Topics: Colonic Neoplasms; Drug Evaluation; Floxuridine; Humans; Isomerism; Kinetics; Neoplasm Metastasis; P

1983
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
    Cancer treatment reports, 1983, Volume: 67, Issue:6

    Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Female;

1983
Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.
    Cancer research, 1984, Volume: 44, Issue:5

    Topics: Animals; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Female; Floxuridine

1984
Determination of a novel fluoropyrimidine, 5'-deoxy-5-fluorouridine, in plasma by high-performance liquid chromatography.
    Journal of chromatography, 1981, Oct-09, Volume: 225, Issue:2

    Topics: Chromatography, High Pressure Liquid; Floxuridine; Half-Life; Humans; Infusions, Parenteral; Pancrea

1981
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
    Cancer research, 1999, Jul-15, Volume: 59, Issue:14

    Topics: Adenocarcinoma; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Fluorouracil; G

1999
Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study.
    International journal of radiation oncology, biology, physics, 1999, Sep-01, Volume: 45, Issue:2

    Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Feasi

1999
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Pharmacotherapy, 2000, Volume: 20, Issue:10

    Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chr

2000
In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model.
    Cancer research, 2001, May-15, Volume: 61, Issue:10

    Topics: Animals; Cell Division; Disease Models, Animal; Disease Progression; Floxuridine; Fluorodeoxyglucose

2001
Chemotherapy of gastrointestinal cancer.
    Clinics in gastroenterology, 1976, Volume: 5, Issue:3

    Topics: Doxorubicin; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Mitomyc

1976
Clinical management of advanced gastrointestinal cancer.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther

1975
Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump.
    Annals of surgery, 1985, Volume: 201, Issue:5

    Topics: Adenoma, Islet Cell; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Catheterization; Catheters

1985
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac

1986
[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:5 Pt 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla

1987
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
    Cancer, 1974, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine

1974
The clinical effects of prolonged intravenous infusion of 5-fluoro-2'-deoxyuridine.
    Cancer research, 1965, Volume: 25, Issue:7

    Topics: Adenoma, Islet Cell; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fl

1965
Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
    Cancer research, 1967, Volume: 27, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Animals; Bromodeoxyuridine; Carcinoma; Carcinoma, Hepatocellular; Carci

1967